Bone mineral density in premenopausal women with systemic lupus erythematosus
- PMID: 14677178
Bone mineral density in premenopausal women with systemic lupus erythematosus
Abstract
Objective: To study bone mineral density (BMD) in premenopausal women with systemic lupus erythematosus (SLE) and to evaluate the influence of disease activity and use of corticosteroids.
Methods: A cross-sectional study on BMD of 118 premenopausal women with SLE. Patients were divided into 2 groups, 74 who had been treated with corticosteroids and 44 who had not. BMD at lumbar spine, femoral neck, and trochanter was measured.
Results: BMD in patients without and with corticosteroid treatment was 1.13 +/- 0.13 vs 1.05 +/- 0.14 g/cm2 (p = 0.005) at lumbar spine, 0.92 +/- 0.12 vs 0.86 +/- 0.12 g/cm2 (p = 0.005) at femoral neck, and 0.78 +/- 0.13 vs 0.72 +/- 0.12 g/cm2 (p = 0.014) at trochanter, respectively. Stepwise multilinear regression analysis showed that corticosteroid exposure was independently associated with decreased BMD in the corticosteroid treated patients (r2 = 7% for lumbar and 6.6% for trochanter model). No significant difference in BMD in corticosteroid treated patients appeared when they were subgrouped according to whether they were taking calcium supplements. Prevalence of osteoporosis at lumbar spine in corticosteroid treated patients was 1.4%, and was lower than reported for age and sex matched Caucasians.
Conclusion: BMD measurements were significantly lower in premenopausal SLE patients who had had corticosteroid treatment than those who had not. There was a negative correlation between BMD and corticosteroid therapy, but not disease activity. Prevalence of osteoporosis, based on lumbar spine BMD, was lower than that reported in Caucasians.
Similar articles
-
Four years follow-up of bone mineral density change in premenopausal women with systemic lupus erythematosus.J Med Assoc Thai. 2004 Nov;87(11):1374-9. J Med Assoc Thai. 2004. PMID: 15825716
-
A comparison of calcium, calcitriol, and alendronate in corticosteroid-treated premenopausal patients with systemic lupus erythematosus.J Rheumatol. 2008 Dec;35(12):2344-7. doi: 10.3899/jrheum.080634. Epub 2008 Nov 1. J Rheumatol. 2008. PMID: 19004038 Clinical Trial.
-
Influences on bone mineral density in Malaysian premenopausal systemic lupus erythematosus patients on corticosteroids.Lupus. 2009 Feb;18(2):178-81. doi: 10.1177/0961203308094995. Lupus. 2009. PMID: 19151123
-
The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis.Osteoporos Int. 2002 Oct;13(10):777-87. doi: 10.1007/s001980200108. Osteoporos Int. 2002. PMID: 12378366 Review.
-
Steroid-induced osteoporosis--a cause for concern?Malays J Pathol. 1997 Jun;19(1):27-33. Malays J Pathol. 1997. PMID: 10879239 Review. No abstract available.
Cited by
-
Inflammatory rheumatic disorders and bone.Curr Rheumatol Rep. 2012 Jun;14(3):224-30. doi: 10.1007/s11926-012-0252-8. Curr Rheumatol Rep. 2012. PMID: 22477520 Free PMC article. Review.
-
Inflammation regulates fibroblast growth factor 23 production.Curr Opin Nephrol Hypertens. 2016 Jul;25(4):325-32. doi: 10.1097/MNH.0000000000000232. Curr Opin Nephrol Hypertens. 2016. PMID: 27191351 Free PMC article. Review.
-
Elevated risk of clinical fractures and associated risk factors in patients with systemic lupus erythematosus versus matched controls: a population-based study in the United Kingdom.Osteoporos Int. 2014 Apr;25(4):1275-83. doi: 10.1007/s00198-013-2587-z. Epub 2013 Dec 3. Osteoporos Int. 2014. PMID: 24297094
-
Prevalence of and risk factors for low bone mineral density in Japanese female patients with systemic lupus erythematosus.Rheumatol Int. 2011 Mar;31(3):365-76. doi: 10.1007/s00296-009-1244-5. Epub 2009 Dec 18. Rheumatol Int. 2011. PMID: 20020143
-
Glucocorticoid-induced osteoporosis in rheumatic diseases.Clinics (Sao Paulo). 2010;65(11):1197-205. doi: 10.1590/s1807-59322010001100024. Clinics (Sao Paulo). 2010. PMID: 21243296 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical